X0306 4 2022-02-10 0 0001435049 CHINOOK THERAPEUTICS, INC. KDNY 0001823187 King Andrew James C/O CHINOOK THERAPEUTICS, INC. 400 FAIRVIEW AVE. NO., 9TH FLOOR SEATTLE WA 98102 0 1 0 0 Chief Scientific Officer Common Stock 2022-02-10 4 M 0 6801 A 10895 D Common Stock 2022-02-11 4 S 0 2498 12.7411 D 8397 D Restricted Stock Units (RSU) 2022-02-10 4 M 0 6801 0.00 D 2024-02-10 Common Stock 6801 13605 D Restricted stock units convert into common stock on a one-for-one basis. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.64 to $12.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. /s/ Kirk Schumacher, Attorney-in-Fact 2022-02-14